Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 12Active not recruiting 9Completed 8Terminated 5Unknown 4Withdrawn 3Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neoplasms 40Breast Neoplasms 38Prostatic Neoplasms 24Colorectal Neoplasms 23Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Lung Neoplasms 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Sarcoma 6Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Epilepsy 5Dementia 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4

Interventions

irinotecan sucrosofate 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡